Tonix Pharmaceuticals (NASDAQ: TNXP) reports Q3 2025 results update

Rhea-AI Filing Summary

Tonix Pharmaceuticals Holding Corp. filed a current report to disclose that it announced its operating results for the quarter ended September 30, 2025.

The company explains that these quarterly results are described in a press release dated November 10, 2025, which is attached as Exhibit 99.01 and incorporated by reference. The report is signed on behalf of the company by Chief Financial Officer Bradley Saenger.

false 0001430306 0001430306 2025-11-10 2025-11-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): November 10, 2025

TONIX PHARMACEUTICALS HOLDING CORP. 

(Exact name of registrant as specified in its charter)

Nevada	001-36019	26-1434750
(State or Other Jurisdiction  of Incorporation)	(Commission  File Number)	(IRS Employer  Identification No.)

26 Main Street, Chatham, New Jersey, 07928

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (862) 799-8599

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	TNXP	The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On November 10, 2025, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended September 30, 2025. A copy of the press release that discusses these matters is filed as Exhibit 99.01 to, and incorporated by reference in, this report.

Item 9.01 Financial Statements and Exhibits.

(d)		Exhibit No.		Description.
		99.01 104		Press Release of the Company, dated November 10, 2025 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	TONIX PHARMACEUTICALS HOLDING CORP.
Date: November 10, 2025	By:	/s/ Bradley Saenger
	Bradley Saenger
	Chief Financial Officer

FAQ

What did Tonix Pharmaceuticals Holding Corp. (TNXP) disclose in this 8-K?

Tonix Pharmaceuticals Holding Corp. disclosed that it announced its operating results for the quarter ended September 30, 2025, via an attached press release.

Which period do the Tonix (TNXP) operating results in this filing cover?

The operating results discussed in this report cover the quarter ended September 30, 2025.

Where can investors find the detailed Tonix Pharmaceuticals (TNXP) Q3 2025 results?

The detailed results are contained in a press release dated November 10, 2025, which is attached as Exhibit 99.01 and incorporated by reference.

On which stock exchange is Tonix Pharmaceuticals common stock listed?

The common stock of Tonix Pharmaceuticals Holding Corp. is listed on The NASDAQ Capital Market under the trading symbol TNXP.

Who signed this Tonix Pharmaceuticals (TNXP) 8-K report?

The report was signed on behalf of Tonix Pharmaceuticals Holding Corp. by Bradley Saenger, Chief Financial Officer.

What exhibits are included with this Tonix Pharmaceuticals 8-K?

The report includes Exhibit 99.01, the press release of the company dated November 10, 2025, and the cover page interactive data file embedded within the Inline XBRL document.